Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Computational screening of antimicrobial peptide analogs targeting AdeB efflux transporter protein in Acinetobacter baumannii associated with multidrug resistance.Scientific reports · 2026
   Article
2. Antimicrobial Peptides: An Emerging Hope in the Era of New Infections and Resistance.Antibiotics (Basel, Switzerland) · 2025
   Article
3. Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer AgainstAntibiotics (Basel, Switzerland) · 2025
   Article

Corrections and comments

• Erratum issued
  Correction: Roson-Calero et al. Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against2025

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as